Exact Mass: 640.3223618
Exact Mass Matches: 640.3223618
Found 233 metabolites which its exact mass value is equals to given mass value 640.3223618,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
N1,N5,N10-Tris-trans-p-coumaroylspermine
C37H44N4O6 (640.3260683999999)
N1,N5,N10-Tris-trans-p-coumaroylspermine is found in herbs and spices. It is a constituent of Matricaria chamomilla (German chamomile). Constituent of Matricaria chamomilla (German chamomile). N1,N5,N10-Tris-trans-p-coumaroylspermine is found in herbs and spices.
PA(8:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
PA(8:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/8:0)
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/8:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
PA(8:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/8:0)
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/8:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
1beta,2beta,3,beta4,beta,5beta-pentahydroxy-spiro-25(27)-en-5-O-beta-D-glucopyranoside|Aspidoside A
anzurogenin C 24-O-beta-D-glucopyranoside (anzuroside)
(1R,3E,8E,10R,13S)-9.10,13-tris(acetoxy)-2,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-5-yl (2E)-3-phenylprop-2-enoate|(3E,8E)-9,10beta,13alpha-triacetoxy-2alpha,7beta,20-trihydroxy-5alpha-[(2E)-cinnamoyloxy]-3,8-secotaxa-3,8,11-triene
1beta,2beta,3,beta4,beta,5beta,7alpha-hexaol-spirost-25(27)-en-6-one-4-O-beta-D-xylopyranoside|tupisteroide A
(2E,5E)-7-hydroperoxy-3,7-dimethyl-2,5-octadienyl-O-(alpha-L-rhamnopyranosyl)-(1??3?)-(4??-O-trans-p-coumaroyl)-beta-D-glucopyranoside|liguroside A
3beta-benzoyloxy-5alpha,8alpha-diacetoxy-15beta-hydroxy-7beta-isobutanoyloxyjatropha-6(17),11E-diene-9,14-dione
3beta-benzoyloxy-7beta-n-butanoyloxy-5alpha,8alpha-diacetoxy-15beta-hydroxyjatropha-6(17),11E-diene-9,14-dione
pierisformotoxin A|rel-(3aR,4S,4aS,7S,8R,9S,9aR,10R,11S,11aR,12S)-8,9,10,11-tetrakis(acetyloxy)decahydro-4-hydroxy-11a-(1-hydroxy-1-methylethyl)-4,8-dimethyl-12-(1-oxopropoxy)-4H-7,9a-methanoheptaleno[3,2-b]furan-2(3H)-one
(2S,3S,4R,5R,7R,9S,11S,15R)-5,15-diacetoxy-3,7-dibenzoyloxy-14-oxolathyra-6(17),12E-diene|euphorbia factor L2
pierisformotoxin B|rel-(3aR,4S,4aS,7S,8R,9S,9aR,10R,11S,11aR,12S)-8,9,11,12-tetrakis(acetyloxy)decahydro-4-hydroxy-11a-(1-hydroxy-1-methylethyl)-4,8-dimethyl-10-(1-oxopropoxy)-4 H-7,9a-methanoheptaleno[3,2-b]furan-2(3H)-one
kidjoranin 3-O-beta-D-digitoxopyranoside|kidjoranin 3-O-beta-digitoxopyranoside
2-[4-(beta-D-glucopyranosyloxy)-3-hydroxy-2,5-bis(3-methylbut-2-en-1-yl)phenyl]-2-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]acetic acid|sabphenoside C
Arg Phe Tyr Arg
Ingol 7,8,12-triacetate 3-(4-methoxyphenyl)acetate
Phe Arg Arg Tyr
Phe Arg Tyr Arg
Phe Tyr Arg Arg
His Ile Trp Trp
His Leu Trp Trp
His Trp Ile Trp
His Trp Leu Trp
His Trp Trp Ile
His Trp Trp Leu
Ile His Trp Trp
Ile Trp His Trp
Ile Trp Trp His
Leu His Trp Trp
Leu Trp His Trp
Leu Trp Trp His
Arg Phe Arg Tyr
Arg Arg Phe Tyr
Arg Arg Tyr Phe
Arg Tyr Phe Arg
Arg Tyr Arg Phe
Trp His Ile Trp
Trp His Leu Trp
Trp His Trp Ile
Trp His Trp Leu
Trp Ile His Trp
Trp Ile Trp His
Trp Leu His Trp
Trp Leu Trp His
Trp Trp His Ile
Trp Trp His Leu
Trp Trp Ile His
Trp Trp Leu His
Tyr Phe Arg Arg
Tyr Arg Phe Arg
Tyr Arg Arg Phe
N1,N5,N10-Tris-trans-p-coumaroylspermine
C37H44N4O6 (640.3260683999999)
catechin(3,4,5,7-tetraacetate)-3-dodecanoate
Cyclo(-Gly-Arg-Gly-Asp-Ser-Pro-Ala)
C25H40N10O10 (640.2928740000001)
3-butyl-2-[3-(3-butyl-1,1-dimethylbenzo[e]indol-3-ium-2-yl)prop-2-enylidene]-1,1-dimethylbenzo[e]indole,perchlorate
N,N,N,N-Tetraphenyl-1,1:4,1:4,1-quaterphenyl-4,4-di amine
1(2H)-Phthalazinone, 4-((4-chlorophenyl)methyl)-2-(((2R)-1-(4-(4-(3-(hexahydro-1H-azepin-1-yl)propoxy)phenyl)butyl)-2-pyrrolidinyl)methyl)-
3-[(21S,22S)-12-(dihydroxymethyl)-26-ethyl-4-hydroxy-16-(1-hydroxyethyl)-17,19,21-trimethyl-11-(2-methylpropyl)-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
C37H44N4O6 (640.3260683999999)
Euphorbia diterpenoid 1
A tetracyclic diterpenoid isolated from the whole plant of Euphorbia decipiens and exhibits inhibitory activity against prolyl endopeptidase (EC 3.4.21.26).
Kidjoranin-3-O-beta-digitoxopyranoside
A steroid glycoside isolated from the roots of Cynanchum auriculatum and has been shown to exhibit cytotoxicity against human tumour cell lines. Kidjoranin-3-O-beta-digitoxopyranoside is a steroid glycoside isolated from the roots of Cynanchum auriculatum and has been shown to exhibit cytotoxicity against human tumour cell lines. It has a role as a metabolite and an antineoplastic agent. It is a 17beta-hydroxy steroid, a cinnamate ester, a methyl ketone, a deoxy hexoside, a steroid ester, a steroid saponin and a tertiary alpha-hydroxy ketone. It derives from a hydride of a pregnane.
3-oxo-5alpha-androstan-17beta-yl 2-O-beta-D-glucopyranuronosyl-beta-D-glucopyranosiduronate
1-(4-fluorophenyl)-3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-henicos-11-enoate
C30H57O12P (640.3587451999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate
[2-Heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] heptanoate
[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] octanoate
[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] dodecanoate
[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate
[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-heptadec-9-enoate
[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate
[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate
[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-undecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
C30H56O12S (640.3492296000001)
[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-undecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
C30H56O12S (640.3492296000001)
[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl 2-methylpropanoate
(4as,6as,6br,8ar,9r,10r,11r,12ar,12br,14br)-10,11-dihydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(3,4,5-trihydroxybenzoyloxy)methyl]-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
(1s,4s,12r,16s)-9-[(5r,9r,16r)-14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl]-7-hydroxy-8-methoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6,8,10-tetraen-18-one
(1s,2r,5r,6r,13r,14s,15s,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl 2-methylpropanoate
(2z)-4-[(1r,2r,7s,14s,15s,16s,18s)-11-hydroxy-10-[(2r)-2-hydroxy-3-methylbut-3-en-1-yl]-15,16-dimethoxy-6,6,7,20,20-pentamethyl-13,17-dioxo-3,8,19-trioxahexacyclo[14.4.1.0²,¹⁴.0²,¹⁸.0⁴,¹².0⁵,⁹]henicosa-4(12),5(9),10-trien-18-yl]-2-methylbut-2-enoic acid
(2s)-4-[(1r,3r,4ar,5s,6r,8s,8ar)-5-[(2s,3as,5r,6ar)-5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl]-8-(acetyloxy)-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-8a-ylmethoxy]-4-oxobutan-2-yl (3s)-3-(acetyloxy)butanoate
4-[(2s,6as,8s,10as)-8-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7,7,10a-trimethyl-1h,2h,4h,5h,6h,6ah,8h,9h,10h-naphtho[2,1-c]pyran-2-yl]-5h-furan-2-one
9-{14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl}-8-hydroxy-7-methoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6(11),7,9-tetraen-18-one
aspidoside a
{"Ingredient_id": "HBIN017153","Ingredient_name": "aspidoside a","Alias": "NA","Ingredient_formula": "C33H52O12","Ingredient_Smile": "CC1C2C(CC3C2(CCC4C3CCC5(C4(C(C(C(C5O)O)O)O)C)OC6C(C(C(C(O6)CO)O)O)O)C)OC17CCC(=C)CO7","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1902","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1s,2r,5r,6r,13r,14s,15s,17r,18s)-6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl 2-methylpropanoate
3-(8-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-7,7,10a-trimethyl-1h,2h,4h,5h,6h,6ah,8h,9h,10h-naphtho[2,1-c]pyran-2-yl)-5h-furan-2-one
(1s)-1-{[4-(5-{[(1s)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-methoxyphenoxy)phenyl]methyl}-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-5-ol
(1r,2r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
(1r)-5-(4-{[(1r)-6-hydroxy-7-methoxy-8-[(6-methoxy-2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)oxy]-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenoxy)-4-methoxycyclohexa-2,4-diene-1-carbaldehyde
C37H40N2O8 (640.2784520000001)
(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-8-(furan-3-yl)-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
1-acetyl-7-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-1,3a,3b-trihydroxy-9a,11a-dimethyl-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl 3-phenylprop-2-enoate
(1s,2r,3s,4s,7s,8z,10s,11r,12r,13s,16r,17s)-2,12-bis(acetyloxy)-3,4,11,16,17-pentahydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,14-dien-10-yl octanoate
(2s)-4-[(1r,3r,4ar,5s,6r,8s,8ar)-5-[(2s,3as,6as)-5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl]-8-(acetyloxy)-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-8a-ylmethoxy]-4-oxobutan-2-yl (3s)-3-(acetyloxy)butanoate
5-carbamimidamido-2-[(4-{[7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-1-hydroxy-4-oxobutylidene)amino]pentanoic acid
methyl 2-[(1s,2s,4ar,5r,8s,8as)-1,8-dihydroxy-5-{[(2r)-2-hydroxy-3-(4-hydroxyphenyl)propanoyl]oxy}-4a-methyl-8-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydronaphthalen-2-yl]prop-2-enoate
4-(8-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-7,7,10a-trimethyl-1h,2h,4h,5h,6h,6ah,8h,9h,10h-naphtho[2,1-c]pyran-2-yl)-5h-furan-2-one
5-[4-({6-hydroxy-7-methoxy-8-[(6-methoxy-2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)oxy]-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl}methyl)phenoxy]-4-methoxycyclohexa-2,4-diene-1-carbaldehyde
C37H40N2O8 (640.2784520000001)
(2s)-4-[(1r,3r,4ar,5s,6r,8s,8ar)-5-[(2s,3as,5s,6ar)-5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl]-8-(acetyloxy)-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-8a-ylmethoxy]-4-oxobutan-2-yl (3s)-3-(acetyloxy)butanoate
4-[(2r,6as,8s,10as)-8-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7,7,10a-trimethyl-1h,2h,4h,5h,6h,6ah,8h,9h,10h-naphtho[2,1-c]pyran-2-yl]-5h-furan-2-one
(4as,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-10,11-dihydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(3,4,5-trihydroxybenzoyloxy)methyl]-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
9,10,13-tris(acetyloxy)-2,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-5-yl 3-phenylprop-2-enoate
(2s,3s,4r,5r,6s)-4,5-dihydroxy-6-[(2r)-2-hydroxy-3-[(13-methyltetradecyl)oxy]propoxy]-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid
(2s)-5-carbamimidamido-2-[(4-{[(1r,2s,4r,6r,7r,10s,11s,14s,16r)-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-1-hydroxy-4-oxobutylidene)amino]pentanoic acid
4,5-dihydroxy-6-{2-hydroxy-3-[(13-methyltetradecyl)oxy]propoxy}-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid
9-{14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl}-7-hydroxy-8-methoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6,8,10-tetraen-18-one
(1s,2r,3e,5r,7s,8e,10s,13r)-9,10,13-tris(acetyloxy)-2,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-5-yl (2e)-3-phenylprop-2-enoate
(1s,2r,5r,6r,13r,14s,15r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl 2-methylpropanoate
6-ethyl-21',24'-dihydroxy-5,11',13'-trimethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl 2-methylbut-2-enoate
2-(4-{[(1s)-7-[(6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-8-yl)oxy]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenoxy)-4-(methoxymethyl)phenol
(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl 2-methylpropanoate
methyl 2-(1,8-dihydroxy-5-{[2-hydroxy-3-(4-hydroxyphenyl)propanoyl]oxy}-4a-methyl-8-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydronaphthalen-2-yl)prop-2-enoate
4-[(2r,6ar,8s,10as)-8-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7,7,10a-trimethyl-1h,2h,4h,5h,6h,6ah,8h,9h,10h-naphtho[2,1-c]pyran-2-yl]-5h-furan-2-one
(1s,3ar,3bs,7s,9ar,9br,11r,11as)-1-acetyl-7-{[(2r,4s,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3a,3b-trihydroxy-9a,11a-dimethyl-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-3-phenylprop-2-enoate
(1'r,2r,4's,5s,6r,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-6-ethyl-21',24'-dihydroxy-5,11',13'-trimethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl (2e)-2-methylbut-2-enoate
3-[(2r,6ar,8s,10as)-8-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7,7,10a-trimethyl-1h,2h,4h,5h,6h,6ah,8h,9h,10h-naphtho[2,1-c]pyran-2-yl]-5h-furan-2-one
4-[11-hydroxy-10-(2-hydroxy-3-methylbut-3-en-1-yl)-15,16-dimethoxy-6,6,7,20,20-pentamethyl-13,17-dioxo-3,8,19-trioxahexacyclo[14.4.1.0²,¹⁴.0²,¹⁸.0⁴,¹².0⁵,⁹]henicosa-4(12),5(9),10-trien-18-yl]-2-methylbut-2-enoic acid
(1s,2r,5r,6r,13r,14s,15r,17r,18s)-6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-13-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl 2-methylpropanoate
(1s,4r,12r,16s)-9-[(5r,9r,16r)-14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl]-8-hydroxy-7-methoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6(11),7,9-tetraen-18-one
(2z)-4-[(1r,2r,7r,14s,15s,16s,18s)-11-hydroxy-10-(2-hydroxy-3-methylbut-3-en-1-yl)-15,16-dimethoxy-6,6,7,20,20-pentamethyl-13,17-dioxo-3,8,19-trioxahexacyclo[14.4.1.0²,¹⁴.0²,¹⁸.0⁴,¹².0⁵,⁹]henicosa-4(12),5(9),10-trien-18-yl]-2-methylbut-2-enoic acid
4-[(2s,6ar,8s,10as)-8-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7,7,10a-trimethyl-1h,2h,4h,5h,6h,6ah,8h,9h,10h-naphtho[2,1-c]pyran-2-yl]-5h-furan-2-one
4-[8-(acetyloxy)-3-hydroxy-5-{5-hydroxy-hexahydrofuro[2,3-b]furan-2-yl}-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-8a-ylmethoxy]-4-oxobutan-2-yl 3-(acetyloxy)butanoate
(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl 2-methylpropanoate
6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl 2-methylpropanoate
1-(2-{[2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl)-n-(5-carbamimidamido-1-hydroxypentan-2-yl)pyrrolidine-2-carboximidic acid
C32H44N6O8 (640.3220464000001)